DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

TBNA vs EBUS-TBNA Plus Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

Phase 3

Recruiting

Conditions: Lung Cancer

Interventions: Procedure: Endobronchial ultrasound with transbronchial needle aspiration
Procedure: Bronchoscopy
Procedure: Cryobiopsy

First Posted Date: 2023-10-30

Last Posted Date: 2024-11-07

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 250

Registration Number: NCT06105801

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules

Recruiting

Conditions: Pulmonary Nodule

Interventions: Procedure: Blood collection
Procedure: Chest Computed Tomography

First Posted Date: 2023-10-10

Last Posted Date: 2024-07-30

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 100

Registration Number: NCT06074133

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

and more 1 locations

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Phase 4

Recruiting

Conditions: Digestive System Neuroendocrine Tumor G2
Digestive System Neuroendocrine Tumor G1
Pancreatic Neuroendocrine Tumor G2
Metastatic Digestive System Neuroendocrine Neoplasm
Metastatic Malignant Neoplasm in the Liver
Pancreatic Neuroendocrine Tumor G1

Interventions: Procedure: Tumor Debulking
Drug: Lutetium Lu 177 Dotatate
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Copper Cu 64 Dotatate
Procedure: Positron Emission Tomography

First Posted Date: 2023-08-30

Last Posted Date: 2024-07-03

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 6

Registration Number: NCT06016855

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Early Phase 1

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Brain Metastases

Interventions: Procedure: Magnetic Resonance Imaging (MRI)
Procedure: Positron Emission Tomography (PET)
Drug: 18F-fluoromisonidazole

First Posted Date: 2023-08-18

Last Posted Date: 2023-08-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 48

Registration Number: NCT05996432

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients with Head and Neck Cancer

Phase 1

Recruiting

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Panitumumab-IRDye800
Other: Indium In 111 Panitumumab
Procedure: Single Photon Emission Computed Tomography
Procedure: Computed Tomography
Procedure: Resection
Procedure: Fluorescence Imaging

First Posted Date: 2023-07-14

Last Posted Date: 2024-12-13

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 40

Registration Number: NCT05945875

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Phase 2

Recruiting

Conditions: Anatomic Stage I Breast Cancer
Anatomic Stage II Breast Cancer
Anatomic Stage III Breast Cancer
Invasive Breast Lobular Carcinoma

Interventions: Procedure: Endocrine Therapy
Procedure: Biopsy of breast
Drug: Neratinib
Procedure: Biospecimen Collection
Procedure: Mammogram
Procedure: Magnetic Resonance Imaging
Procedure: Breast Surgery
Procedure: Ultrasound

First Posted Date: 2023-06-26

Last Posted Date: 2024-11-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT05919108

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Emory University/ Winship Cancer Institute, Atlanta, Georgia, United States

and more 2 locations

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

Phase 1

Recruiting

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions: Biological: Panitumumab
Other: Indium In 111 Panitumumab
Procedure: Single Photon Emission Computed Tomography
Procedure: Computed Tomography
Procedure: Surgical Procedure
Other: Imaging agent
Procedure: Intraoperative Imaging
Procedure: Near Infrared Imaging
Procedure: Electrocardiography
Procedure: Biospecimen Collection

First Posted Date: 2023-06-13

Last Posted Date: 2024-12-13

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT05901545

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Phase 2

Recruiting

Conditions: Metastatic Triple-Negative Breast Carcinoma
Metastatic HER2-Negative Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Sacituzumab Govitecan

First Posted Date: 2023-03-15

Last Posted Date: 2025-04-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 160

Registration Number: NCT05770531

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Phase 2

Suspended

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8
Refractory Melanoma
Metastatic Melanoma
Unresectable Melanoma
Clinical Stage IV Cutaneous Melanoma AJCC v8

Interventions: Drug: Rigosertib
Biological: Pembrolizumab
Procedure: Magnetic Resonance Imaging
Procedure: Biospecimen Collection
Procedure: Biopsy

First Posted Date: 2023-03-10

Last Posted Date: 2024-10-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 29

Registration Number: NCT05764395

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1

Recruiting

Conditions: Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage III Lung Cancer

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Biological: Pembrolizumab
Drug: Nab-paclitaxel
Drug: Pemetrexed
Procedure: Positron Emission Tomography
Biological: Atezolizumab
Radiation: Radiation Therapy
Biological: Cemiplimab
Other: [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2022-08-15

Last Posted Date: 2024-10-17

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 25

Registration Number: NCT05501665

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy